Search

Your search keyword '"Spatola C"' showing total 4 results
Start Over Author "Spatola C" Topic eye diseases
4 results on '"Spatola C"'

1. Dosimetric and clinical experience in eye proton treatment at INFN-LNS.

Author

Cirrone, G. A. P., Cuttone, G., Di Rosa, F., Lojacono, P., Mongelli, V., Lo Nigro, S., Ott, J., Patti, I. V., Pittera, S., Privitera, G., Raffaele, L., Reibaldi, A., Russo, G., Salamone, V., Sabini, M. G., Spatola, C., and Valastro, L. M.

Subjects
PROTONS, PARTICLES (Nuclear physics), MEDICAL dosimetry, NEUROENDOCRINE tumors, EYE diseases, PATIENTS
Abstract

After six years of activity 155 patients have been treated inside the CATANA (Centro di AdroTerapia ed Applicazioni Nucleari Avanzate) facility. CATANA is the first and unique proton therapy facility in which the 62 MeV proton beams, accelerated by a Superconducting Cyclotron, are used for the radio-therapeutic treatments of choroidal and iris melanomas. Inside CATANA new absolute and relative dosimetric techniques have been developed in order to achieve the best results in terms of treatment precision and dose release accuracy. The follow-up results for 42 patients demonstrated the efficacy of high energy protons in the radiotherapeutic field and encouraged us in our activity in the battle against cancer [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

2. A 62-MeV Proton Beam for the Treatment of Ocular Melanoma at Laboratori Nazionali del Sud-INFN.

Author

Cirrone, G. A. P., Cuttone, G., Lojacono, P. A., Lo Nigro, S., Mongelli, V., Patti, I. V., Priviteria, G., Raffaele, L., Rifuggiato, D., Sabini, M. C., Salamone, V., Spatola, C., and Valastro, L. M.

Subjects
PROTON beams, MELANOMA, EYE diseases, PARTICLE beams
Abstract

At the Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali del Sud (INFN-LNS) in Catania, Italy, the first Italian protontherapy facility, named Centro di AdroTerapia e Applicazioni Nucleari Avanzate (CATANA) has been built in collaboration with the University of Catania. It is based on the use of the 62-MeV proton beam delivered by the K = 800 Superconducting Cyclotron installed and working at INFN-LNS since 1995. The facility is mainly devoted to the treatment of ocular diseases like uveal melanoma. A beam treatment line in air has been assembled together with a dedicated positioning patient system. The facility has been in operation since the beginning of 2002 and 66 patients have been successfully treated up to now. The main features of CATANA together with the clinical and dosimetric features will be extensively described; particularly, the proton beam line, that has been entirely built at LNS, with all its elements, the experimental transversal and depth dose distributions of the 62-MeV proton beam obtained for a final collimator of 25-mm diameter and the experimental depth dose distributions of a modulated proton beam obtained for the same final collimator. Finally, the clinical results over 1 yr of treatments, describing the features of the treated diseases will be reported. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

3. Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma

Author

Michele Reibaldi, Rosario Caltabiano, Andrea Russo, Argyrios Chronopoulos, Matteo Fallico, Teresio Avitabile, Vincenza Bonfiglio, Corrado Spatola, Antonio Longo, Fallico M., Reibaldi M., Avitabile T., Longo A., Bonfiglio V., Chronopoulos A., Caltabiano R., Spatola C., and Russo A.

Subjects
Male, Intraocular pressure, Fovea Centralis, Visual acuity, genetic structures, medicine.medical_treatment, Brachytherapy, Visual Acuity, Intravitreal aflibercept, Plaque brachytherapy, Radiation maculopathy, Aged, Choroid Neoplasms, Dose-Response Relationship, Drug, Dose-Response Relationship, Radiation, Female, Fluorescein Angiography, Follow-Up Studies, Fundus Oculi, Humans, Intravitreal Injections, Macular Edema, Melanoma, Middle Aged, Prospective Studies, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Ruthenium Radioisotopes, Tomography, Optical Coherence, Treatment Outcome, 0302 clinical medicine, Endophthalmitis, Receptors, Tomography, Aflibercept, Radiation, medicine.diagnostic_test, Vascular Endothelial Growth Factor, Fluorescein angiography, Sensory Systems, Dose-Response Relationship, Drug, Optical Coherence, medicine.symptom, Human, medicine.drug, medicine.medical_specialty, Ruthenium Radioisotope, Follow-Up Studie, 03 medical and health sciences, Cellular and Molecular Neuroscience, Ophthalmology, medicine, Macular edema, Fovea Centrali, business.industry, Plaque radiotherapy, Intravitreal Injection, medicine.disease, eye diseases, Prospective Studie, 030221 ophthalmology & optometry, Maculopathy, sense organs, business, Choroid Neoplasm, 030217 neurology & neurosurgery, Recombinant Fusion Protein
Abstract

Purpose: To assess the efficacy of intravitreal aflibercept in patients suffering from post-radiation macular edema following plaque radiotherapy for choroidal melanoma. Methods: This prospective, interventional case series included patients affected by radiation maculopathy (RM) with macular edema secondary to ruthenium-106 plaque brachytherapy for choroidal melanoma. The effect of intravitreal aflibercept on best-corrected visual acuity (BCVA), central foveal thickness (CFT) detected by spectral domain optical coherence tomography (sd-OCT), and Horgan’s grading scale of RM was evaluated throughout the 24-month follow-up. Intraocular pressure (IOP) and possible complications were also recorded. Results: Nine eyes of 9 patients were included. A mean of 4.4 ± 1.2 injections were given over the 24 months. At the end of follow-up, mean BCVA was significantly improved, from 0.9 ± 0.19 logMAR at baseline to 0.56 ± 0.3 logMAR (P = 0.028), and mean CFT was significantly decreased, from 546 ± 123 μm at baseline to 223 ± 34 μm (P < 0.001). Intravitreal aflibercept lowered baseline maculopathy stage as well. No significant change in IOP values and no complications, such as endophthalmitis, was recorded. Conclusion: Intravitreal aflibercept is an effective treatment for patients with radiation-induced macular edema, allowing functional and anatomical improvements to be achieved with a relatively low number of injections.

Published
2018

4. DEXAMETHASONE INTRAVITREAL IMPLANT VS RANIBIZUMAB IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRACHYTHERAPY FOR CHOROIDAL MELANOMA

Author

Teresio Avitabile, Livio Giulio Marco Franco, Antonio Longo, Corrado Spatola, Michele Reibaldi, Caterina Gagliano, Andrea Russo, Maurizio G. Uva, Giuseppe Privitera, Vincenza Bonfiglio, Russo A., Reibaldi M., Avitabile T., Uva M.G., Franco L.M., Gagliano C., Bonfiglio V., Spatola C., Privitera G., and Longo A.

Subjects
Male, Visual acuity, genetic structures, medicine.medical_treatment, Brachytherapy, Ocular hypertension, Angiogenesis Inhibitors, Drug Implant, 0302 clinical medicine, Glucocorticoid, Dexamethasone Intravitreal Implant, Radiation Injurie, Melanoma, Drug Implants, Choroid Neoplasms, General Medicine, Middle Aged, Intravitreal Injections, Drug Therapy, Combination, Female, medicine.symptom, medicine.drug, Angiogenesis Inhibitor, Human, medicine.medical_specialty, dexamethasone, 03 medical and health sciences, radiation maculopathy, Ophthalmology, Ranibizumab, medicine, Humans, choroidal melanoma, Radiation Injuries, Glucocorticoids, Macular edema, Dexamethasone, Aged, Retrospective Studies, macular edema, business.industry, Intravitreal Injection, medicine.disease, eye diseases, 030221 ophthalmology & optometry, Maculopathy, business, Choroid Neoplasm, 030217 neurology & neurosurgery
Abstract

PURPOSE To evaluate the efficacy of an intravitreal dexamethasone (Dex) implant 0.7 mg compared with intravitreal ranibizumab (Ra) for the treatment of radiation maculopathy with macular edema secondary to plaque brachytherapy in choroidal melanoma. METHODS Eight patients were treated with intravitreal Ra, and eight patients received the Dex intravitreal implant. Visual acuity and foveal thickness were evaluated using spectral domain optical coherence tomography. RESULTS The mean calculated irradiation to the fovea and mean times from brachytherapy to maculopathy development did not differ significantly between groups. In the Ra group, a mean 7.8 ± 3.9 injections were given and the mean follow-up was 33 ± 15 months (range, 7-52 months). In the Dex group, a mean 2.1 ± 0.8 injections were given and the mean follow-up was 22 ± 7 months (range, 11-31 months). The mean visual acuity improved significantly from the baseline to the last follow-up visit in both groups. Foveal thickness decreased significantly in both groups from 459 ± 81 μm to 243 ± 58 μm and from 437 ± 71 μm to 254 ± 44 μm from the baseline to the last follow-up visit in the Ra and Dex groups, respectively. No patients developed significant cataract or ocular hypertension in both groups. CONCLUSION Both Ra and Dex are effective treatments for macular edema secondary to plaque brachytherapy for uveal melanoma. Dex-treated patients required fewer injections to achieve anatomical and functional improvement.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results